QSIAW — Quantum-Si incorporated

Quantum-Si (QSIAW) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $552,000 for Q3 2025, down from previous quarters due to capital sales headwinds.
• Gross Profit: $194,000, resulting in a gross margin of 35%. For the first nine months of 2025, revenue totaled $2.0 million with a gross profit of $1.0 million (52% gross margin).
• Operating Expenses: GAAP total operating expenses were $40 million, up from $28.5 million in Q3 2024. Adjusted operating expenses were $21.4 million, down from $26.0 million year-over-year.
• Cash Position: As of September 30, 2025, the company had $230.5 million in cash and investments.
• Guidance: Adjusted operating expenses projected at $96 million or less for 2025, with total cash use expected to be $103 million or less, reflecting a $10.2 million lease termination payment.

2. Strategic Updates and Business Highlights

• Commercial Adoption: The company launched alternative capital acquisition models, resulting in 12 new customers, primarily in academic labs, which are crucial for future consumable sales and scientific validation.
• Innovation Roadmap: Successful sequencing runs on multiple prototype Proteus systems were reported, marking a significant milestone. The version 4 sequencing kit was launched, enhancing amino acid detection capabilities.
• Scientific Affairs: Five manuscripts submitted for publication, with two published and three under review, indicating ongoing efforts to validate technology through scientific research.
• Partnerships: The company is exploring partnerships to enhance development activities and broaden market participation.

3. Forward Guidance and Outlook

• The company remains optimistic about the long-term market opportunity in proteomics, despite short-term capital market headwinds. The focus is on building a large installed base to support future product launches, particularly the Proteus platform.
• Upcoming Investor and Analyst Day on November 19, 2025, will provide further updates on the Proteus program and other initiatives.

4. Bad News, Challenges, or Points of Concern

• Market Headwinds: Continued capital sales headwinds and uncertainties in NIH funding are impacting revenue and customer acquisition, particularly in academic settings.
• Operating Expenses: Significant operating expenses, including a $13.6 million lease termination payment, highlight financial pressures despite cost control efforts.
• Sales Cycle: The sales cycle in biotech and pharma remains long (9-12 months), which may affect short-term revenue growth.

5. Notable Q&A Insights

• Investor Day Expectations: The upcoming Investor Day is expected to provide early sequencing data from the Proteus system and updates on the recognizer development program.
• DARPA Program: The company is aware of the DARPA PROS program but sees limited alignment with its current strategy focused on high-throughput capabilities for research labs.
• Placement Program: Over half of the new placements were in academic labs, with a focus on generating data for publications, which is crucial for building momentum for the Proteus launch. The company does not have a specific target for the number of placements but aims to leverage high-value academic centers.

Overall, while Quantum-Si faces significant challenges in the current market environment, it is making strides in customer acquisition and product development, positioning itself for future growth.